This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-17. Anything still debated is marked as such rather than presented as settled.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
=== Viral diseases in cats === LTCI, manufactured by T-Cyte Therapeutics, has been conditionally approved by the United States Department of Agriculture (USDA) as an aid in the treatment of cats infected with feline leukemia virus (FeLV) and/or feline immunodeficiency virus (FIV), and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia, or thrombocytopenia. Peer-reviewed literature disputes the benefit claims from the manufacturer. T-Cyte data as of 2011 does not strongly support the medication's ability to significantly increase the length or quality of life of treated cats.
In Switzerland, a special authorization program allows limited medical use of substances like LSD for patients with serious, treatment-resistant conditions, with patients treated under physician supervision.
Mn(CO)5Cl + AlCl3 + CO → [Mn(CO)+6][AlCl−4] The use of strong acids succeeded in preparing gold carbonyl cations such as [Au(CO)2]+, which is used as a catalyst for the carbonylation of alkenes. The cationic platinum carbonyl complex [Pt(CO)4]2+ can be prepared by working in so-called superacids such as antimony pentafluoride. Although CO is considered generally as a ligand for low-valent metal ions, the tetravalent iron complex [Cp*2Fe]2+ (16-valence electron complex) quantitatively binds CO to give the diamagnetic Fe(IV)-carbonyl [Cp*2FeCO]2+ (18-valence electron complex).
=== Notable individuals === Charlie "Bird" Parker, the jazz saxophonist, is said to have used nutmeg recreationally. Malcolm X once tried nutmeg while in prison in 1946, remarking that it "had the kick of three or four reefers". Richard Meltzer, the rock critic, is known to have tried nutmeg, expressing that it caused him to experience all music as identical. William S. Burroughs tried nutmeg once and found it vaguely similar to cannabis but with more side effects.
is the mass of the electron antineutrino. In other words, the total energy released is the mass energy of the initial nucleus, minus the mass energy of the final nucleus, electron, and antineutrino. The mass of the nucleus mN is related to the standard atomic mass m by
Sources: en.wikipedia.org
== Breast == Breast cancer Ductal carcinoma in situ Inflammatory breast cancer Invasive ductal carcinoma Invasive lobular carcinoma Tubular carcinoma Invasive cribriform carcinoma of the breast (also termed invasive cribriform carcinoma) Medullary carcinoma Male breast cancer Phyllodes tumor Mammary secretory carcinoma Mucinous carcinoma of the breast Papillary carcinomas of the breast
High-dose or prolonged parenterally-administered lorazepam with its associated solvent can cause propylene glycol intoxication and poisoning. In September 2020, the US Food and Drug Administration (FDA) required the boxed warning be updated for all benzodiazepine medicines to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.
Alfonso Vidal also said that at his final meeting with Agent Poll, Poll told him that he could manipulate the public into believing anything, and even convince the country that Alfonso Vidal was a thief, as "...money can go missing anytime." Alfonso Vidal also stated that he firmly believed that Grand Treasurer Airán Cervera was either in the employment of the Ministry of the Interior or the National Revolutionary Police Force. He said that Grand Treasurer Airán Cervera could not be trusted.
Impaired NO synthesis Nitric oxide is known as an important stimulator of cell proliferation, maturation and differentiation. Thus, nitric oxide increases fibroblast proliferation and thereby collagen production in wound healing. Also, L-arginine and nitric oxide are required for proper cross-linking of collagen fibers, via proline, to minimize scarring and maximize the tensile strength of healed tissue. Endothelial cell specific nitric oxide synthase (EcNOS) is activated by the pulsatile flow of blood through vessels. Nitric oxide produced by EcNOS, maintains the diameter of blood vessels and proper blood flow to tissues. In addition to this, nitric oxide also regulates angiogenesis, which plays a major role in wound healing. Thus, diabetic patients exhibit reduced ability to generate nitric oxide from L-arginine. Reasons that have been postulated in the literature include accumulation of nitric oxide synthase inhibitor due to high glucose associated kidney dysfunction and reduced production of nitric oxide synthase due to ketoacidosis observed in diabetic patients and pH dependent nature of nitric oxide synthase. Structural and functional changes in fibroblasts Diabetic ulcer fibroblasts show various morphological differences compared to fibroblasts from age-matched controls. Diabetic ulcer fibroblasts are usually large and widely spread in the culture flask compared to the spindle-shaped morphology of the fibroblasts in age-matched controls.
=== Remote vehicle disabling systems === Remote vehicle disabling systems provide users at remote locations the ability to prevent an engine from starting, prevent movement of a vehicle, and to stop or slow an operating vehicle. Remote disabling allows a dispatcher or other authorized personnel to gradually decelerate a vehicle by downshifting, limiting the throttle capability, or bleeding air from the braking system from a remote location. Some of these systems provide advance notification to the driver that the vehicle disabling is about to occur. After stopping a vehicle, some systems will lock the vehicle's brakes or will not allow the vehicle's engine to be restarted within a certain time-frame. Remote disabling systems can also be integrated into a remote panic and emergency notification system. In an emergency, a driver can send an emergency alert by pressing a panic button on the dashboard, or by using a key-fob panic button if the driver is within close proximity of the truck. Then, the carrier or other approved organization can be remotely alerted to allow a dispatcher or other authorized personnel to evaluate the situation, communicate with the driver, and/or potentially disable the vehicle.
Sources: en.wikipedia.org
==== Disadvantages of Microbubbles for Drug Delivery ==== Microbubbles do not extravasate easily due to their large size, and hence their effects are relegated to the vasculature. Nanodroplets, perfluorocarbon liquid droplets surrounded by a lipid shell that vaporize due to an ultrasound pulse, offer a small diameter to promote extravasation and afford an alternative to microbubbles. Microbubbles have short half-lives on the order of minutes in circulation, which limits the treatment time. Microbubbles are filtered by the liver and spleen, and any drug conjugation would then also potentially pose a toxicity threat to these organs, should the microbubbles not have already released their cargo. Drug conjugations to microbubbles are complicated for translation, and these formulations would be difficult to scale up for widespread use. There can be a small amount hemorrhage into brain tissue when microbubbles are used to disrupt the blood brain barrier, though this is thought to be reversible.
Marcus S. Albernaz, MD Shirley A. Carraway, Ed.D. James W. "Jim" Chestnutt Charlester T. Crumpler, Jr. Ernest L. "Ernie" Evans Jimmy F. Garris Robert J. "Bob" Greczyn, Jr. W. Phillip "Phil" Hodges J. Bryant Kittrell, III C. Bynum Satterwhite Anand "Andy" Tewari, MD
=== Desalination of sea water === Work by Viviane Renaudin has led to the development of a new type of multiple-effect plate evaporator, which can be used for the desalination of brackish or sea water. The proposed distillation process is based on the principle of multiple-effect dripping film plate evaporators. The innovation lies in the horizontal transfer of vapour to the condensation zone. From a socio-economic point of view, thanks to its human-scale dimensions, its modular construction and its ease of assembly, the system has the advantage of being usable by unskilled operators in developing countries. The process also has political value: it enables countries to end their dependence on their neighbours for their drinking water supplies.
== Scientific societies == The Society for Cryobiology was founded in 1964 to bring together those from the biological, medical, and physical sciences who have a common interest in the effects of low temperatures on biological systems. As of 2007, the Society for Cryobiology had about 280 members from around the world, and one-half of them are US-based. The purpose of the Society is to promote scientific research in low temperature biology, to improve scientific understanding in this field, and to disseminate and apply this knowledge to the benefit of mankind. The Society requires of all its members the highest ethical and scientific standards in the performance of their professional activities. According to the Society's bylaws, membership may be refused to applicants whose conduct is deemed detrimental to the Society; in 1982, the bylaws were amended explicitly to exclude "any practice or application of freezing deceased persons in the anticipation of their reanimation", over the objections of some members who were cryonicists, such as Jerry Leaf. The Society organizes an annual scientific meeting dedicated to all aspects of low-temperature biology. This international meeting offers opportunities for presentation and discussion of the most up-to-date research in cryobiology, as well as reviewing specific aspects through symposia and workshops. Members are also kept informed of news and forthcoming meetings through the Society newsletter, News Notes. The 2011–2012 president of the Society for Cryobiology was John H. Crowe.
=== Self-treatment === If an individual recognizes the symptoms of hypoglycemia coming on, blood sugar should promptly be measured, and a sugary food or drink should be consumed. The person must be conscious and able to swallow. The goal is to consume 10–20 grams of a carbohydrate to raise blood glucose levels to a minimum of 70 mg/dL (3.9 mmol/L). Examples of products to consume are:
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.